NCT04754022招募中不适用
An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Younger Patients Undergoing Cardiac Surgery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,440
- 试验地点
- 99
- 主要终点
- Composite score of any one of the following events occurring 6 months after cardiac surgery: (1) all-cause mortality; (2) myocardial infarction; (3) new onset renal failure requiring dialysis; or (4) new focal neurological deficit (stroke).
研究概览
简要总结
TRICS-IV is an international, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in moderate to high risk patients who are 65 years of age or younger undergoing cardiac surgery on cardiopulmonary bypass, using a superiority trial design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 and ≤65 years of age
- •Planned cardiac surgery using cardiopulmonary bypass
- •Informed consent obtained
- •Preoperative European System for Cardiac Operative Risk Evaluation (EuroSCORE I) of 6 or more
排除标准
- •Patients who refuse participation
- •Patients who are unable to receive or who refuse blood products
- •Patients who are involved in a preoperative autologous pre-donation program
- •Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device
- •Pregnancy or lactation (a negative pregnancy test must be obtained prior to randomization for women of childbearing potential)
结局指标
主要结局
Composite score of any one of the following events occurring 6 months after cardiac surgery: (1) all-cause mortality; (2) myocardial infarction; (3) new onset renal failure requiring dialysis; or (4) new focal neurological deficit (stroke).
时间窗: Within 6 months after cardiac surgery.
Any of all-cause mortality, myocardial infarction, new onset renal failure requiring dialysis, or new focal neurological deficit (stroke).
次要结局
- Composite and individual all-cause mortality, myocardial infarction, new onset renal failure requiring dialysis, and new focal neurological deficit (stroke).(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Length of stay in the ICU and hospital.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Acute kidney injury.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Duration of mechanical ventilation.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Incidence of infection.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Prolonged low output state.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Delirium.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Hospital visits.(Within 6 months after cardiac surgery.)
- Incidence of encephalopathy.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Incidence of each individual component of the primary outcome: all-cause mortality, myocardial infarction, new onset renal failure requiring dialysis, and new focal neurological deficit (stroke).(Within 6 months after cardiac surgery.)
- Incidence of gut infarction.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Incidence of seizures.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
- Transfusion requirements.(Up to hospital discharge or after 28 days postoperatively, whichever comes first.)
研究者
研究点 (99)
Loading locations...
相似试验
已完成
不适用
Transfusion Requirements in Cardiac Surgery IIIHeart, Functional, Postoperative, Cardiac Surgery DisorderNCT02042898Unity Health Toronto5,028
已完成
不适用
Clinical Trial Comparing C-Brace to Knee Ankle Foot Orthosis (KAFO)/Stance Control Orthosis (SCO)Pareses, Lower ExtremityNCT03906656Otto Bock Healthcare Products GmbH108
撤回
3 期
REmission in Membranous Nephropathy International Trial (REMIT)Primary Membranous NephropathyNCT06120673The University of Queensland224
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of FracturePostmenopausalNCT05352516Shanghai Henlius Biotech478
终止
3 期
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCAdvanced NSCLCNCT05106335Jiangsu HengRui Medicine Co., Ltd.1